[go: up one dir, main page]

US4040785A - Lysable blood preservative composition - Google Patents

Lysable blood preservative composition Download PDF

Info

Publication number
US4040785A
US4040785A US05/733,435 US73343576A US4040785A US 4040785 A US4040785 A US 4040785A US 73343576 A US73343576 A US 73343576A US 4040785 A US4040785 A US 4040785A
Authority
US
United States
Prior art keywords
weight
formaldehyde
blood
dextrose
blood composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/733,435
Inventor
Young Ran Kim
Leonard Ornstein
Henry Cook Waters, III
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Technicon Instruments Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technicon Instruments Corp filed Critical Technicon Instruments Corp
Priority to US05/733,435 priority Critical patent/US4040785A/en
Priority to CA278,578A priority patent/CA1075608A/en
Priority to GB22593/77A priority patent/GB1583320A/en
Priority to AU25998/77A priority patent/AU505380B2/en
Priority to DE19772727730 priority patent/DE2727730A1/en
Application granted granted Critical
Publication of US4040785A publication Critical patent/US4040785A/en
Priority to FR7730033A priority patent/FR2367426A1/en
Priority to IT69322/77A priority patent/IT1093013B/en
Priority to JP12416777A priority patent/JPS5352492A/en
Assigned to TECHNICON INSTRUMENTS CORPORATION reassignment TECHNICON INSTRUMENTS CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). Assignors: REVGROUP PANTRY MIRROR CORP.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/124—Disinfecting agents, e.g. antimicrobials
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2525—Stabilizing or preserving

Definitions

  • the present invention is directed to a preserved lysable anticoagulated blood composition
  • a preserved lysable anticoagulated blood composition comprising a mixture of blood sample and preservative reagent wherein said preservative reagent comprises an aqueous mixture of a mono-, di- or trisaccharide component and formaldehyde, the resulting preserved blood composition containing said saccharide in the range of from 0.05% to 1.0% by weight and said formaldehyde in the range of from 0.1% to 0.8% by weight.
  • the preservative reagent consists of dextrose (a monosaccharide) and formaldehyde.
  • the resultihg preserved blood composition contains dextrose and formaldehyde in amounts of 1% by weight and 0.2% by weight respectively. In another preferred embodiment, the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 0.66% by weight and 0.13% by weight respectively.
  • Hemalog D 1 which is a screening laboratory instrument designed to ease the burden of differential white blood cell counting, cytochemical procedures specifically identify and label individual cell types.
  • the stream of stained and unstained cells flows through an optical view chamber where a photoelectric measuring process takes place.
  • Electronic signals are sorted by amplitude and classified into categories corresponding to the several cell types.
  • Data are printed for one sample/min. on the five major white cell types of whole blood, as well as juvenile forms of neutrophils and an unclassified remainder, in the form of percentage and cells/min. 3 .
  • the red cells remain lysable. This is highly desirable since in most automated white blood cell counting systems, as in the Hemalog D, red cells must be lysed or they will interfere with the cell counting and identification process.
  • the specific chemical-identifying process stains the white cells.
  • the blood sample must be essentially in the same state as when drawn from a patient. It is known that as blood ages, degradation occurs which could lead to an incorrect analysis. For instance, in the Hemalog D apparatus, since classification of cells are based on enzymatic activity, as the blood stands or ages, this activity is subject to change and therefore questionable results. Furthermore, blood specimens on standing are subjected to other undesirable occurrences, such as clumping and cell breaking.
  • the present invention is directed to a preserved lysable anticoagulated blood composition whereby the analytic life of the blood specimen to be analyzed is extended to periods up to and beyond 72 hours at 4° C. and up to and beyond 48 hours at 25° C.
  • the advantages and benefits derived from such a preservative system are apparent -- the technician need not be concerned with running the sample through the apparatus within 24 hours which could be a problem if a large number of samples are received.
  • the preserved lysable anticoagulated blood composition of this invention comprises a mixture of blood sample and a preservative reagent, the latter comprising an aqueous mixture of a mono-, di- or trisaccharide component, preferably a monosaccharide, and formaldehyde, all readily available materials.
  • Anticoagulent is supplied into the system by incorporation into the blood sample or the preservative reagent and in cases where a blood sample is drawn and thereafter immediately combined with preservative reagent, the latter embodiment is preferred.
  • An illustrative useful anticoagulent for purposes of this invention is tripotassium ethylenediamine tetraacetic acid (K 3 EDTA).
  • K 3 EDTA tripotassium ethylenediamine tetraacetic acid
  • concentration of K 3 EDTA is typically in the range from 0.1 to 0.2% by weight.
  • Illustrative monosaccharides for purposes of this invention include dextrose, fructose and galactose with dextrose being most preferred.
  • Exemplary disaccharides include sucrose and maltose.
  • An illustrative trisaccharide is raffinose.
  • the saccharide component and formaldehyde are combined in aqueous form using distilled or deionized water and preferably filtered, for instance, through a 0.8 ⁇ filter.
  • the reagent preservative is combined with a fresh whole blood sample.
  • the preserved lysable anticoagulated blood composition so formed is gently mixed, e.g. by inversion, and then stored at temperatures from 1° C. to 25° C. until ready for testing.
  • Such blood preserving compositions can be stored for periods beyond 24 hours and up to about 72 hours.
  • a preserved lysable anticoagulated blood composition which can be stored at 4° C. for at least 72 hours comprising a mixture of blood sample and preservative reagent, the latter consisting of an aqueous mixture of dextrose and formaldehyde wherein the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 1% by weight and 0.2% by weight respectively is prepared as follows:
  • aqueous mixture in distilled or deionized form, containing 10% by weight dextrose and 2% by weight formaldehyde is filtered through an 0.8 ⁇ filter and combined with an anticoagulated whole blood sample.
  • the volume ratio of blood sample to reagent preservative is 10:1.
  • the resulting lysable preserved blood composition is gently mixed by inversion and stored at 4° C.
  • fructose fructose
  • galactose galactose
  • a preserved lysable anticoagulated blood composition which can be stored at 25° C. for at least 48 hours comprising a mixture of blood sample and preservative reagent, the latter consisting of an aqueous mixture of dextrose, formaldehyde and tripotassium ethylenediamine tetraacetic acid (K 3 EDTA) wherein the resulting preserved blood composition contains dextrose, formaldehyde and K 3 EDTA in amounts of 0.66% by weight, 0.13% by weight and 0.15% by weight respectively is prepared as follows:
  • aqueous mixture in distilled or deionized form, containing 20% by weight dextrose, 4% by weight formaldehyde and 4.5% by weight K 3 EDTA is filtered through an 0.8 ⁇ filter and placed in a container under vacuum. A freshly drawn whole blood sample is then directly introduced into the vacuum container.
  • the volume ratio of blood sample to reagent preservative is 30:1.
  • the resulting lysable preserved anticoagulated blood composition is gently mixed by inversion and stored at 25° C.
  • fructose fructose
  • galactose galactose
  • a preserved lysable anticoagulated blood composition which can be stored at 25° C. for at least 48 hours comprising a mixture of blood sample and preservative reagent, the latter consisting of an aqueous mixture of dextrose, formaldehyde, K 3 EDTA and sodium chloride wherein the resulting preserved blood composition contains dextrose, formaldehyde, K 3 EDTA and sodium chloride in amounts of 0.09% by weight, 0.6% by weight, 0.15% by weight and 0.4% by weight respectively is prepared as follows:
  • aqueous mixture in distilled or deionized form, containing 0.1% by weight of dextrose, 0.66% by weight of formaldehyde, 0.17% by weight K 3 EDTA and 0.45% by weight of sodium chloride is filtered through an 0.8 ⁇ filter and combined with whole blood sample and the volume ratio of blood sample to reagent preservative is 1 to 9.
  • the resulting lysable preserved anticoagulated blood composition is gently mixed by inversion and stored at 25° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Blood is preserved by combining samples with a preservative reagent consisting of an aqueous mixture of a mono-, di- or trisaccharide component and formaldehyde.

Description

BACKGROUND OF THE INVENTION
With the advent of hematologic automation by use of continuous flow systems, it became possible for technicians to substantially increase the number of samples which could be analyzed over a fixed period of time. However, concomitant with this vast improvement in efficiency, there arose the need for stabilizing or preserving whole blood samples in order to facilitate the logistics of specimen transportation from remote locations and the batching of specimens for presentation to automated hematologic systems.
SUMMARY OF THE INVENTION
It is the purpose of this invention to extend the life of blood specimens so that accurate white blood cell differential counts can be obtained on continuous flow automated systems for blood specimens more than 1 day old.
In accordance with that objective, the present invention is directed to a preserved lysable anticoagulated blood composition comprising a mixture of blood sample and preservative reagent wherein said preservative reagent comprises an aqueous mixture of a mono-, di- or trisaccharide component and formaldehyde, the resulting preserved blood composition containing said saccharide in the range of from 0.05% to 1.0% by weight and said formaldehyde in the range of from 0.1% to 0.8% by weight.
In a preferred embodiment, the preservative reagent consists of dextrose (a monosaccharide) and formaldehyde.
In one preferred embodiment, the resultihg preserved blood composition contains dextrose and formaldehyde in amounts of 1% by weight and 0.2% by weight respectively. In another preferred embodiment, the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 0.66% by weight and 0.13% by weight respectively.
DETAILED DESCRIPTION OF THE INVENTION
In a continuous automated flow system apparatus such as Hemalog D1 which is a screening laboratory instrument designed to ease the burden of differential white blood cell counting, cytochemical procedures specifically identify and label individual cell types. The stream of stained and unstained cells flows through an optical view chamber where a photoelectric measuring process takes place. Electronic signals are sorted by amplitude and classified into categories corresponding to the several cell types. Data are printed for one sample/min. on the five major white cell types of whole blood, as well as juvenile forms of neutrophils and an unclassified remainder, in the form of percentage and cells/min.3.
In the preserved blood compositions of this invention, the red cells remain lysable. This is highly desirable since in most automated white blood cell counting systems, as in the Hemalog D, red cells must be lysed or they will interfere with the cell counting and identification process.
The specific chemical-identifying process stains the white cells.
To ensure correct analyses on such systems, the blood sample must be essentially in the same state as when drawn from a patient. It is known that as blood ages, degradation occurs which could lead to an incorrect analysis. For instance, in the Hemalog D apparatus, since classification of cells are based on enzymatic activity, as the blood stands or ages, this activity is subject to change and therefore questionable results. Furthermore, blood specimens on standing are subjected to other undesirable occurrences, such as clumping and cell breaking.
Because these unwanted occurrences are apt to become more pronounced as the blood sample stands for any length of time, it has become necessary to find ways to preserve the basic nature of the sample for an extended period of time so that when analysis is effected, the results are dependable.
Accordingly, the present invention is directed to a preserved lysable anticoagulated blood composition whereby the analytic life of the blood specimen to be analyzed is extended to periods up to and beyond 72 hours at 4° C. and up to and beyond 48 hours at 25° C. The advantages and benefits derived from such a preservative system are apparent -- the technician need not be concerned with running the sample through the apparatus within 24 hours which could be a problem if a large number of samples are received.
The preserved lysable anticoagulated blood composition of this invention comprises a mixture of blood sample and a preservative reagent, the latter comprising an aqueous mixture of a mono-, di- or trisaccharide component, preferably a monosaccharide, and formaldehyde, all readily available materials.
Anticoagulent is supplied into the system by incorporation into the blood sample or the preservative reagent and in cases where a blood sample is drawn and thereafter immediately combined with preservative reagent, the latter embodiment is preferred. An illustrative useful anticoagulent for purposes of this invention is tripotassium ethylenediamine tetraacetic acid (K3 EDTA). In the final total blood composition, the concentration of K3 EDTA is typically in the range from 0.1 to 0.2% by weight.
Illustrative monosaccharides for purposes of this invention include dextrose, fructose and galactose with dextrose being most preferred. Exemplary disaccharides include sucrose and maltose. An illustrative trisaccharide is raffinose.
The saccharide component and formaldehyde are combined in aqueous form using distilled or deionized water and preferably filtered, for instance, through a 0.8 μ filter.
After filtration, the reagent preservative is combined with a fresh whole blood sample.
The preserved lysable anticoagulated blood composition so formed is gently mixed, e.g. by inversion, and then stored at temperatures from 1° C. to 25° C. until ready for testing.
Such blood preserving compositions can be stored for periods beyond 24 hours and up to about 72 hours.
EXAMPLE I
A preserved lysable anticoagulated blood composition which can be stored at 4° C. for at least 72 hours comprising a mixture of blood sample and preservative reagent, the latter consisting of an aqueous mixture of dextrose and formaldehyde wherein the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 1% by weight and 0.2% by weight respectively is prepared as follows:
An aqueous mixture, in distilled or deionized form, containing 10% by weight dextrose and 2% by weight formaldehyde is filtered through an 0.8 μ filter and combined with an anticoagulated whole blood sample. The volume ratio of blood sample to reagent preservative is 10:1.
The resulting lysable preserved blood composition is gently mixed by inversion and stored at 4° C.
EXAMPLE II
Preserved lysable anticoagulated blood compositions similar to that described in Example I are prepared wherein in lieu of dextrose, the following saccharides are used:
monosaccharides: fructose, galactose
disaccharides: sucrose, maltose
trisaccharides: raffinose
EXAMPLE III
A preserved lysable anticoagulated blood composition which can be stored at 25° C. for at least 48 hours comprising a mixture of blood sample and preservative reagent, the latter consisting of an aqueous mixture of dextrose, formaldehyde and tripotassium ethylenediamine tetraacetic acid (K3 EDTA) wherein the resulting preserved blood composition contains dextrose, formaldehyde and K3 EDTA in amounts of 0.66% by weight, 0.13% by weight and 0.15% by weight respectively is prepared as follows:
An aqueous mixture, in distilled or deionized form, containing 20% by weight dextrose, 4% by weight formaldehyde and 4.5% by weight K3 EDTA is filtered through an 0.8 μ filter and placed in a container under vacuum. A freshly drawn whole blood sample is then directly introduced into the vacuum container. The volume ratio of blood sample to reagent preservative is 30:1.
The resulting lysable preserved anticoagulated blood composition is gently mixed by inversion and stored at 25° C.
EXAMPLE IV
Preserved lysable anticoagulated blood compositions similar to that described in Example III are prepared wherein in lieu of dextrose, the following saccharides are used:
monosaccharides: fructose, galactose
disaccharides: sucrose, maltose
trisaccharides: raffinose
EXAMPLE V
A preserved lysable anticoagulated blood composition which can be stored at 25° C. for at least 48 hours comprising a mixture of blood sample and preservative reagent, the latter consisting of an aqueous mixture of dextrose, formaldehyde, K3 EDTA and sodium chloride wherein the resulting preserved blood composition contains dextrose, formaldehyde, K3 EDTA and sodium chloride in amounts of 0.09% by weight, 0.6% by weight, 0.15% by weight and 0.4% by weight respectively is prepared as follows:
An aqueous mixture, in distilled or deionized form, containing 0.1% by weight of dextrose, 0.66% by weight of formaldehyde, 0.17% by weight K3 EDTA and 0.45% by weight of sodium chloride is filtered through an 0.8 μ filter and combined with whole blood sample and the volume ratio of blood sample to reagent preservative is 1 to 9.
The resulting lysable preserved anticoagulated blood composition is gently mixed by inversion and stored at 25° C.
It should be understood by those skilled in the art that various modifications may be made in the present invention without departing from the spirit and scope thereof as described in the specification and defined in the appended claims.

Claims (13)

What is claimed is:
1. A preserved lysable anticoagulated blood composition comprising a mixture of blood sample and preservative reagent wherein said preservative reagent comprises an aqueous mixture of a mono-, di- or trisaccharide component and formaldehyde, the resulting preserved blood composition containing said saccharide in the range of from 0.05% to 1.0% by weight and said formaldehyde in the range of from 0.1% to 0.8% by weight.
2. The blood composition of claim 1 wherein said saccharide component is a monosaccharide.
3. The blood composition of claim 2 wherein said monosaccharide is dextrose and the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 1% by weight and 0.2% by weight respectively.
4. The blood composition of claim 2 wherein said monosaccharide is dextrose and the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 0.66% by weight and 0.13% by weight respectively.
5. In a method for enhancing the preservative characteristics of whole blood samples comprising a mixture of whole blood sample and preservative reagent, the improvement which comprises adding a filtered aqueous mixture of a mono-, di- or trisaccharide component and formaldehyde to a fresh whole blood sample, the resulting preserved anticoagulated blood composition containing said saccharide in the range of from 0.05% to 1.0% by weight and said formaldehyde in the range of from 0.1% to 0.8% by weight, mixing the resulting preserved blood composition and storing same until ready for testing.
6. The method of claim 5 wherein anticoagulent is contained in the preservative reagent.
7. The method of claim 5 wherein anticoagulent is contained in the blood sample.
8. The method of claim 5 wherein said saccharide component is a monosaccharide.
9. The method of claim 8 wherein said monosaccharide is dextrose and the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 1% by weight and 0.2% by weight respectively and is stored at 4° C.
10. The method of claim 8 wherein said monosaccharide is dextrose and the resulting preserved blood composition contains dextrose and formaldehyde in amounts of 0.66% by weight and 0.13% by weight respectively and is stored at 25° C.
11. The method of claim 5 wherein said aqueous mixture is filtered through an 0.8 μ filter.
12. The method of claim 5 wherein said resulting preserved blood composition is stored at a temperature in the range from 1° C. to 25° C.
13. The method of claim 5 wherein said mixing step is accomplished by inversion.
US05/733,435 1976-10-18 1976-10-18 Lysable blood preservative composition Expired - Lifetime US4040785A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US05/733,435 US4040785A (en) 1976-10-18 1976-10-18 Lysable blood preservative composition
CA278,578A CA1075608A (en) 1976-10-18 1977-05-17 Saccharide and formaldehyde containing lysable blood preservative composition
GB22593/77A GB1583320A (en) 1976-10-18 1977-05-27 Lysable whole blood compositions
AU25998/77A AU505380B2 (en) 1976-10-18 1977-06-09 Lysable blood preservative composition
DE19772727730 DE2727730A1 (en) 1976-10-18 1977-06-21 SOLUBLE, DURABLE BLOOD COMPOSITION
FR7730033A FR2367426A1 (en) 1976-10-18 1977-10-06 PROTECTED BLOOD COMPOSITION, LYSABLE AND RENDERED INCOAGULABLE
IT69322/77A IT1093013B (en) 1976-10-18 1977-10-17 PROCEDURE AND COMPOSITION TO IMPROVE THE CONSERVABILITY OF BLOOD SAMPLES
JP12416777A JPS5352492A (en) 1976-10-18 1977-10-18 Composite for soluble blood reserving

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/733,435 US4040785A (en) 1976-10-18 1976-10-18 Lysable blood preservative composition

Publications (1)

Publication Number Publication Date
US4040785A true US4040785A (en) 1977-08-09

Family

ID=24947585

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/733,435 Expired - Lifetime US4040785A (en) 1976-10-18 1976-10-18 Lysable blood preservative composition

Country Status (8)

Country Link
US (1) US4040785A (en)
JP (1) JPS5352492A (en)
AU (1) AU505380B2 (en)
CA (1) CA1075608A (en)
DE (1) DE2727730A1 (en)
FR (1) FR2367426A1 (en)
GB (1) GB1583320A (en)
IT (1) IT1093013B (en)

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099917A (en) * 1977-07-21 1978-07-11 Technicon Instruments Corporation Process for preparing a cell suspension from blood for discrimination of white blood cells and platelets from other blood particles
US4127502A (en) * 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
US4185964A (en) * 1977-02-08 1980-01-29 Central Laboratories of Associated Maryland Pathologists, Ltd. Lysing reagent
EP0072440A1 (en) * 1981-07-16 1983-02-23 Sherwood Medical Industries Inc. Standard or control material for glycosylated or total hemoglobin determination
US4632907A (en) * 1984-08-31 1986-12-30 Shionogi & Co., Ltd. Preservative solution for fixed avian erythrocytes for the viral hemagglutination test
US4637986A (en) * 1983-08-22 1987-01-20 Ortho Diagnostic Systems, Inc. Flow cytometry lysing reagent with leukoprotective agent for producing a 3-part WBC count
EP0214613A2 (en) * 1985-09-06 1987-03-18 Bayer Corporation Method for determination of a differential white blood cell count
US4663295A (en) * 1983-06-29 1987-05-05 Ciba Corning Diagnostics Corp. Estrogen-progesterone control reagents and methods for making same
US4801549A (en) * 1985-09-06 1989-01-31 Technicon Instruments Corporation Method for the determination of a differential white blood cell count
US4978624A (en) * 1985-09-06 1990-12-18 Technicon Instruments Corporation Reagent for the determination of a differential white blood cell count
US5268299A (en) * 1988-04-14 1993-12-07 Eastman Kodak Company Diluent composition useful in the detection of antibodies in assays
US5328821A (en) * 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
WO2000001710A2 (en) * 1998-07-01 2000-01-13 Troy Chemie Gmbh Products from the reaction of formaldehyde with carbohydrates or carbohydrate derivatives, and use of said products as preservatives
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
WO2003018757A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Stabilization of cells and biological specimens for analysis
US6602718B1 (en) * 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US6632844B1 (en) 2000-03-29 2003-10-14 Washington University Methods and compositions for preserving glucose level in blood specimens
US6743575B2 (en) 1996-06-14 2004-06-01 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
US20040229203A1 (en) * 1996-06-14 2004-11-18 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
US20050181463A1 (en) * 2004-02-17 2005-08-18 Rao Galla C. Analysis of circulating tumor cells, fragments, and debris
US20060188995A1 (en) * 2005-02-24 2006-08-24 Ryan Wayne L Process, composition and kit for providing a stable whole blood calibrator/control
US20060194192A1 (en) * 2004-02-17 2006-08-31 Immunivest Corporation Stabilization of cells and biological specimens for analysis
US20090035803A1 (en) * 2005-07-20 2009-02-05 Kyowa Medex Co., Ltd. Method for stabilization of peptides in a biological sample
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
USRE43389E1 (en) 1998-08-12 2012-05-15 Preanalytix Gmbh Vessel for blood sampling
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2018145005A1 (en) * 2017-02-03 2018-08-09 Streck, Inc. Sample collection tube with preservative
US10064404B2 (en) 2014-06-10 2018-09-04 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10568317B2 (en) 2015-12-08 2020-02-25 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111545B2 (en) 2010-05-18 2021-09-07 Natera, Inc. Methods for simultaneous amplification of target loci
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11286530B2 (en) 2010-05-18 2022-03-29 Natera, Inc. Methods for simultaneous amplification of target loci
US11306357B2 (en) 2010-05-18 2022-04-19 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11306359B2 (en) 2005-11-26 2022-04-19 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11319596B2 (en) 2014-04-21 2022-05-03 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11390916B2 (en) 2014-04-21 2022-07-19 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US11519028B2 (en) 2016-12-07 2022-12-06 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US12020778B2 (en) 2010-05-18 2024-06-25 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12100478B2 (en) 2012-08-17 2024-09-24 Natera, Inc. Method for non-invasive prenatal testing using parental mosaicism data
US12146195B2 (en) 2016-04-15 2024-11-19 Natera, Inc. Methods for lung cancer detection
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2022-03-03 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT361135B (en) * 1979-06-27 1981-02-25 Immuno Ag METHOD FOR PRESERVING THE ELECTRO-PHORETIC PROPERTIES OF LIPOPROTEINS
DE2949824A1 (en) * 1979-12-12 1981-07-02 Marianne Dr. 5000 Köln Sehrbundt METHOD FOR STABILIZING LYMPHOCYTE / THROMBOZYTEN MIXED SUSPENSIONS
US4369127A (en) * 1980-07-21 1983-01-18 Instrumentation Laboratory Inc. Blood gas control
JPS63120254A (en) * 1986-11-10 1988-05-24 Terumo Corp Blood storage container
JPS63297043A (en) * 1987-05-29 1988-12-05 Komori Printing Mach Co Ltd Ink supply quantity controller per zone
JPS63297042A (en) * 1987-05-29 1988-12-05 Komori Printing Mach Co Ltd Ink supply quantity controller per zone
DE4217104A1 (en) * 1992-05-22 1993-11-25 Salama Magdy Reservoir or reservoir system - for inactivation, inhibition and/or elimination of pathogens
US6197540B1 (en) * 1993-07-05 2001-03-06 Northern General Hospital N.H.S. Trust Preparation and stabilization of cells using aged transition metal solutions
ATE170979T1 (en) * 1994-04-05 1998-09-15 North Gen Hospital Nhs Trust PREPARATION AND STABILIZATION OF CELL SUSPENSIONS
GB2313288B (en) * 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
DE10016163A1 (en) * 2000-03-31 2002-01-10 Cellcontrol Biomedical Lab Gmb Biocidal material useful in photographic processing machines comprises a water-permeable matrix containing a dispersed mixture of hydrophilic and hydrophobic biocides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703438A (en) * 1969-04-08 1972-11-21 Bruss I Perelivania Krovi Method for the stabilization of blood
US3847738A (en) * 1971-11-01 1974-11-12 American Hospital Supply Corp Blood collection and preservation unit
US3859049A (en) * 1973-09-14 1975-01-07 Arnold G Ware Blood reference standard and process for blood gas test
US3925153A (en) * 1971-05-14 1975-12-09 Experimentales Et Cliniques De Composition for conservation of blood

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1278211A (en) * 1960-11-08 1961-12-08 Union Carbide Corp Storage of biological substances, in particular blood
NL293434A (en) * 1962-02-05
US3444039A (en) * 1964-12-14 1969-05-13 Ambrose Harry Jesudasan Rajama Freezable live cell diluent and process
GB1244344A (en) * 1967-11-13 1971-08-25 Abbott Lab Hemagglutination testing procedure employing stabilized and potentiated erythrocytes and a method for their preparation
US3925541A (en) * 1971-02-22 1975-12-09 Abbott Lab Method of coating stabilized erythrocytes
US3813465A (en) * 1971-12-16 1974-05-28 I Lerner Cytological preservative and mucolytic composition
US3940943A (en) * 1975-01-22 1976-03-02 The Curators Of The University Of Missouri Multistage freezing system for preservation of biological materials

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703438A (en) * 1969-04-08 1972-11-21 Bruss I Perelivania Krovi Method for the stabilization of blood
US3925153A (en) * 1971-05-14 1975-12-09 Experimentales Et Cliniques De Composition for conservation of blood
US3847738A (en) * 1971-11-01 1974-11-12 American Hospital Supply Corp Blood collection and preservation unit
US3859049A (en) * 1973-09-14 1975-01-07 Arnold G Ware Blood reference standard and process for blood gas test

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185964A (en) * 1977-02-08 1980-01-29 Central Laboratories of Associated Maryland Pathologists, Ltd. Lysing reagent
US4127502A (en) * 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
US4099917A (en) * 1977-07-21 1978-07-11 Technicon Instruments Corporation Process for preparing a cell suspension from blood for discrimination of white blood cells and platelets from other blood particles
EP0072440A1 (en) * 1981-07-16 1983-02-23 Sherwood Medical Industries Inc. Standard or control material for glycosylated or total hemoglobin determination
US4465774A (en) * 1981-07-16 1984-08-14 Sherwood Medical Company Standard or control material for glysocylated or total hemoglobin determination
US4663295A (en) * 1983-06-29 1987-05-05 Ciba Corning Diagnostics Corp. Estrogen-progesterone control reagents and methods for making same
US4637986A (en) * 1983-08-22 1987-01-20 Ortho Diagnostic Systems, Inc. Flow cytometry lysing reagent with leukoprotective agent for producing a 3-part WBC count
US4632907A (en) * 1984-08-31 1986-12-30 Shionogi & Co., Ltd. Preservative solution for fixed avian erythrocytes for the viral hemagglutination test
EP0214613A3 (en) * 1985-09-06 1989-07-26 Technicon Instruments Corporation(A Delaware Corporation) Method for determination of a differential white blood cell count
US4801549A (en) * 1985-09-06 1989-01-31 Technicon Instruments Corporation Method for the determination of a differential white blood cell count
EP0214613A2 (en) * 1985-09-06 1987-03-18 Bayer Corporation Method for determination of a differential white blood cell count
US4978624A (en) * 1985-09-06 1990-12-18 Technicon Instruments Corporation Reagent for the determination of a differential white blood cell count
US5268299A (en) * 1988-04-14 1993-12-07 Eastman Kodak Company Diluent composition useful in the detection of antibodies in assays
US5328821A (en) * 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US6743575B2 (en) 1996-06-14 2004-06-01 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
US20040229203A1 (en) * 1996-06-14 2004-11-18 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
WO2000001710A2 (en) * 1998-07-01 2000-01-13 Troy Chemie Gmbh Products from the reaction of formaldehyde with carbohydrates or carbohydrate derivatives, and use of said products as preservatives
WO2000001710A3 (en) * 1998-07-01 2000-06-15 Troy Chemie Gmbh Products from the reaction of formaldehyde with carbohydrates or carbohydrate derivatives, and use of said products as preservatives
USRE43389E1 (en) 1998-08-12 2012-05-15 Preanalytix Gmbh Vessel for blood sampling
US6632844B1 (en) 2000-03-29 2003-10-14 Washington University Methods and compositions for preserving glucose level in blood specimens
US6602718B1 (en) * 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US20040115689A1 (en) * 2000-11-08 2004-06-17 Augello Frank A. Method and device for collecting and stabilizing a biological sample
WO2003018757A3 (en) * 2001-08-23 2003-09-12 Immunivest Corp Stabilization of cells and biological specimens for analysis
WO2003018757A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Stabilization of cells and biological specimens for analysis
US8329422B2 (en) 2001-08-23 2012-12-11 Veridex Llc Analysis of circulating tumor cells, fragments, and debris
AU2008288601B2 (en) * 2001-08-23 2012-05-31 Veridex, Llc Stabilization of cells and biological specimens for analysis
US20110104718A1 (en) * 2001-08-23 2011-05-05 Veridex, Llc Analysis of Circulating Tumor Cells, Fragments, and Debris
US7863012B2 (en) 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
US20060194192A1 (en) * 2004-02-17 2006-08-31 Immunivest Corporation Stabilization of cells and biological specimens for analysis
US20050181463A1 (en) * 2004-02-17 2005-08-18 Rao Galla C. Analysis of circulating tumor cells, fragments, and debris
US20060188995A1 (en) * 2005-02-24 2006-08-24 Ryan Wayne L Process, composition and kit for providing a stable whole blood calibrator/control
US8173385B2 (en) * 2005-07-20 2012-05-08 Kyowa Medex Co., Ltd. Method for stabilization of peptides in a biological sample
US20090035803A1 (en) * 2005-07-20 2009-02-05 Kyowa Medex Co., Ltd. Method for stabilization of peptides in a biological sample
US12065703B2 (en) 2005-07-29 2024-08-20 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11306359B2 (en) 2005-11-26 2022-04-19 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11519035B2 (en) 2010-05-18 2022-12-06 Natera, Inc. Methods for simultaneous amplification of target loci
US11111545B2 (en) 2010-05-18 2021-09-07 Natera, Inc. Methods for simultaneous amplification of target loci
US11525162B2 (en) 2010-05-18 2022-12-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12020778B2 (en) 2010-05-18 2024-06-25 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11286530B2 (en) 2010-05-18 2022-03-29 Natera, Inc. Methods for simultaneous amplification of target loci
US11306357B2 (en) 2010-05-18 2022-04-19 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11312996B2 (en) 2010-05-18 2022-04-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11746376B2 (en) 2010-05-18 2023-09-05 Natera, Inc. Methods for amplification of cell-free DNA using ligated adaptors and universal and inner target-specific primers for multiplexed nested PCR
US11482300B2 (en) 2010-05-18 2022-10-25 Natera, Inc. Methods for preparing a DNA fraction from a biological sample for analyzing genotypes of cell-free DNA
US12110552B2 (en) 2010-05-18 2024-10-08 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9999217B2 (en) 2010-07-26 2018-06-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
US12100478B2 (en) 2012-08-17 2024-09-24 Natera, Inc. Method for non-invasive prenatal testing using parental mosaicism data
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US11408037B2 (en) 2014-04-21 2022-08-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11319596B2 (en) 2014-04-21 2022-05-03 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11486008B2 (en) 2014-04-21 2022-11-01 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11390916B2 (en) 2014-04-21 2022-07-19 Natera, Inc. Methods for simultaneous amplification of target loci
US11371100B2 (en) 2014-04-21 2022-06-28 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11530454B2 (en) 2014-04-21 2022-12-20 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11414709B2 (en) 2014-04-21 2022-08-16 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11319595B2 (en) 2014-04-21 2022-05-03 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US12121022B2 (en) 2014-06-10 2024-10-22 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10064404B2 (en) 2014-06-10 2018-09-04 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10772319B2 (en) 2014-06-10 2020-09-15 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US11672247B2 (en) 2014-06-10 2023-06-13 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US11946101B2 (en) 2015-05-11 2024-04-02 Natera, Inc. Methods and compositions for determining ploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US11116205B2 (en) 2015-12-08 2021-09-14 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US12089588B2 (en) 2015-12-08 2024-09-17 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US10568317B2 (en) 2015-12-08 2020-02-25 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US12146195B2 (en) 2016-04-15 2024-11-19 Natera, Inc. Methods for lung cancer detection
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US11530442B2 (en) 2016-12-07 2022-12-20 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11519028B2 (en) 2016-12-07 2022-12-06 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
WO2018145005A1 (en) * 2017-02-03 2018-08-09 Streck, Inc. Sample collection tube with preservative
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12221653B2 (en) 2022-03-03 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci

Also Published As

Publication number Publication date
GB1583320A (en) 1981-01-21
JPS6125099B2 (en) 1986-06-13
DE2727730A1 (en) 1978-04-20
FR2367426B1 (en) 1983-12-02
JPS5352492A (en) 1978-05-12
IT1093013B (en) 1985-07-19
CA1075608A (en) 1980-04-15
AU2599877A (en) 1978-12-14
FR2367426A1 (en) 1978-05-12
AU505380B2 (en) 1979-11-15
DE2727730C2 (en) 1989-07-20

Similar Documents

Publication Publication Date Title
US4040785A (en) Lysable blood preservative composition
DE69016415T2 (en) STABLE HEMOGLOBIN REFERENCE SOLUTION.
US5460797A (en) Method for fixing tissues and cells for analysis using oxazolidine compounds
US5459073A (en) Method and composition for preserving antigens and process for utilizing cytological material produced by same
US4099917A (en) Process for preparing a cell suspension from blood for discrimination of white blood cells and platelets from other blood particles
DE3587036T2 (en) METHOD AND REAGENT SYSTEM FOR THE DIFFERENTIAL DETERMINATION OF FOUR POPULATIONS OF LEUCOCYTES.
DE69434942T2 (en) MULTIPURPOSE REAGENT SYSTEM FOR THE FAST LYSING OF FULL BLOOD SAMPLES
KR100194407B1 (en) Reagents Used in Automated Outflow Cell Calculators for Differentiation and Qualification of Leukocyte Subpopulations in Blood and Their Uses
US5188935A (en) Reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes
EP0301182B1 (en) Reagent for reticulocyte counting by flow cytometry
DE3854326T2 (en) TREATMENT TECHNOLOGY FOR WHOLE BLOOD PATTERN.
WO1985005640A1 (en) A reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes
Cholak et al. Microdetermination of lead in biological material with dithizone extraction at high pH
US3000836A (en) Stabilized whole blood standard and method of making the same
CN110987553B (en) Erythrocyte treatment reagent and application thereof
Lichtman et al. An ultrasensitive method for the measurement of human leukocyte calcium: lymphocytes
EP0579246A1 (en) Method for removing unstable type saccharified hemoglobin
Davis et al. Stability of dried blood spots on paper, as used in screening neonates for hypothyroidism.
Nakagawa et al. Determination of rat mast cells by flow-cytometry
SU1109641A1 (en) Method of determination of leycocyte quantity in milk
CN116754527A (en) Preparation method of leucocyte quality control substance based on fluorescence principle
Starkovich et al. Semiautomated thiocyanate method for determining peroxide values of lipids
SU1518710A1 (en) Method of detecting erythro cytes
EP0523356B1 (en) Burst-test
Henderson Methods of determining nickel and cobalt in meteoric iron

Legal Events

Date Code Title Description
AS Assignment

Owner name: TECHNICON INSTRUMENTS CORPORATION

Free format text: MERGER;ASSIGNOR:REVGROUP PANTRY MIRROR CORP.;REEL/FRAME:004912/0740

Effective date: 19871231